Financing Outlook for Florida Life Science and High Tech Companies: An Investor's Point of View
April 18, 2008
You have created a valuable intellectual property asset and assembled a core management team, and now it’s time to secure funding. In this session, a select group of investors and investment bankers in the high-tech and life sciences arena will tell you how they examine and analyze investment opportunities in this space. This discussion will focus on:
- Capital availability for Florida high-tech and life sciences companies (including impact of credit crunch)
- Areas of investor focus
- Lessons from recent deals
- Exit strategies
Related Insights
July 22, 2025
Health Care Law Today
GLP-1 Receptor Agonists: Clinical Trial Considerations
The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide (Victoza®), semaglutide (Ozempic®, Wegovy®), and tirzepatide (Mounjaro®, Zepbound®).
July 21, 2025
Energy Current
DOE Announces Pilot Program to Build Advanced U.S. Nuclear Fuel Supply Lines: What You Need to Know Now
Introduction Coming on the heels of its June 2025 announcement establishing a pilot program for reactor construction and operation in…
July 21, 2025
Labor & Employment Law Perspectives
Considering a Reduction in Force? Some Preliminary Considerations
Employers sometimes find it necessary to make the difficult decision to undergo a reduction-in-force (RIF), resulting in employee layoffs…